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Abstract
Background: Lymphangioleiomyomatosis (LAM) is a rare lung disease characterised by progressive airflow
obstruction. No effective medical treatment is available but therapy with sirolimus has shown some promise. The
aim of this observational study was to evaluate sirolimus in progressive LAM.
Methods: Sirolimus (trough level 5 - 10 ng/ml) was administered to ten female patients (42.4 ± 11.9 years) with
documented progression. Serial pulmonary function tests and six-minute-walk-distance (6-MWD) assessments were
performed.
Results: The mean loss of FEV1 was -2.30 ± 0.52 ml/day before therapy and a significant mean gain of FEV1 of 1.19
± 0.26 ml/day was detected during treatment (p = 0.001). Mean FEV1 and FVC at baseline were 1.12 ± 0.15 l (36.1
± 4.5%pred.) and 2.47 ± 0.25 l (69.2 ± 6.5%pred.), respectively. At three and six months during follow-up a
significant increase of FEV1 and FVC was demonstrated (3 months ΔFEV1: 220 ± 82 ml, p = 0.024; 6 months ΔFEV1:
345 ± 58 ml, p = 0.001); (3 months ΔFVC: 360 ± 141 ml, p = 0.031; 6 months ΔFVC: 488 ± 138 ml, p = 0.006).
Sirolimus was discontinued in 3 patients because of serious recurrent lower respiratory tract infection or sirolimus-
induced pneumonitis. No deaths and no pneumothoraces occurred during therapy.
Conclusions: Our data suggest that sirolimus might be considered as a therapeutic option in rapidly declining
LAM patients. However, sirolimus administration may be associated with severe respiratory adverse events requiring
treatment cessation in some patients. Moreover, discontinuation of sirolimus is mandatory prior to lung
transplantation.
Background
Lymphangioleiomyomatosis (LAM) is a rare lung disease
which almost exclusively affects young women. LAM
occurs in an isolated form as sporadic LAM or in asso-
ciation with the genetic disease tuberous sclerosis com-
plex (TSC). The pulmonary manifestation of LAM is
characterized by infiltration of smooth-muscle cells and
formation of parenchymal cysts. It results in dyspnea on
exertion due to airflow obstruction, recurrent pneu-
mothoraces and less frequently chylous pleural fluid col-
lections. Approximately 40% of patients with sporadic
LAM and more than 80% of TSC patients develop
angiomyolipoma mainly of t h ek i d n e y sw i t har i s ko f
hemorrhage and renal failure. Genetic analyses suggest
that cells of pulmonary LAM lesions and renal angio-
myolipoma derive from a common source [1,2].
Treatment options include supportive use of broncho-
dilators, oxygen supplementation and specific surgical or
interventional procedures for pneumo- and chylothorax
or renal lesions, respectively. Moreover, avoidance or
reduction of oestrogen exposure and administration of
progesterone analogues have been used without clear
evidence of therapeutic benefit. Nevertheless, since pro-
gressive pulmonary LAM or therapy refractory pneu-
mothoraces ultimately lead to respiratory failure, lung
transplantation remains the only available therapeutic
option for end-stage LAM in carefully selected patients
[3-5].
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the TSC 1/2 genes resulting in constitutive activation of
the mammalian target of rapamycin (mTOR) pathway
has inspired studies to investigate the effect of mTOR
inhibition with sirolimus in this disease [6]. The focus of
these trials was primarily to demonstrate the ability of
sirolimus to reduce renal angiomyolipoma volume [7,8].
However, the prospective open-label study of Bissler et
al. provided some evidence in eleven patients suggesting
that suppression of mTOR signalling might as well con-
stitute a beneficial treatment option for pulmonary
involvement in LAM [7]. In contrast, interim findings in
a multicenter trial presented by Davies et al. did not
reveal improvement of pulmonary function in three of
four patients with available data [8].
Inspired by these findings, we started sirolimus ther-
apy based on an individual risk benefit assessment in
patients with documented progressive pulmonary LAM
referred to our center for lung transplantation evalua-
tion. The aim of the present study is to report our
experience with sirolimus in this cohort of deteriorating
patients suffering from respiratory failure in the absence
of established medical alternatives.
Methods
Patient population
From November 2006 through December 2009, 10 con-
secutive patients with progressive pulmonary LAM
referred to our center for lung transplantation evalua-
tion, were included in this study. A confirmed diagnosis
of the LAM associated with TSC or sporadic LAM, the
use of contraception, the absence of relevant pleural
effusion and the presence of a minimum of three pul-
monary function tests (PFT) with at least two tests per-
formed in our center prior to initiation of sirolimus
were required for inclusion [9-11]. Informed written
consent was obtained from each subject. The study was
performed in accordance with recommendations of the
local board on medical ethics at Ludwig Maximilians
University of Munich.
Sirolimus therapy and follow-up
Sirolimus was administered orally with a target trough
level of 5 - 10 ng/ml. At the beginning sirolimus levels
were measured twice a week and every other week
thereafter after achievement of target level. Baseline was
defined as start of sirolimus therapy and follow-up visits
were scheduled every three months. At the time of
initiation of sirolimus, hormone therapy including pro-
gesterone was discontinued.
Pulmonary function tests (PFT) including spirometry,
body plethysmography, single breath diffusing capacity
for carbon monoxide (DLCO) and blood gas analysis in
arterialized capillary blood from the ear lobe while
breathing room air were performed at baseline and dur-
ing follow-up [12]. Parameters were calculated as per-
cent of predicted [13]. Assessment of reversible airflow
obstruction was conducted prior to baseline. In case of
positive response, bronchodilator therapy was initiated
before baseline measurement and continuously adminis-
tered throughout the study period. The distance covered
in 6 minutes (6-MWD) was measured according to the
American Thoracic Society statement at baseline and
after six months of sirolimus therapy [14]. Thoracic
imaging was only performed in case of new respiratory
symptoms, decline from baseline forced expiratory
volume in 1 second (FEV1) or progressive hypoxemia.
Renal angiomyolipoma size was not systematically fol-
lowed. Moreover, routine follow-up included electrocar-
diogram, laboratory testing for red and white cell count,
creatinine, electrolytes, and liver enzymes.
Statistical Analysis and assessment of response to
sirolimus therapy
Data analysis was performed retrospectively without pre-
specified endpoints based on functional outcome or lung
function testing. Statistics were calculated using SPSS
Statistics software version 17.0. for Windows (SPSS Inc.,
Chicago, IL). Given the variable natural course of the
disease assessing response to therapy is difficult in indi-
vidual patients. Therefore, we plotted all available values
of FEV1 measured before and after the therapeutic inter-
vention over time and obtained the related slopes by lin-
ear regression analysis expressed as mean rate of change
of FEV1 in ml/day. Benefit of sirolimus therapy was
defined by comparison of the slopes before and after the
intervention. The pre- and post-treatment slopes and
outcomes were compared using a two-tailed paired Stu-
dent’s t-tests. Data are presented as mean ± SEM (stan-
dard error of the mean) or as individual values. Results
were considered statistically significant at p < 0.05.
Results
Patient Cohort
A total of ten female patients were included in this
s t u d y( t a b l e1 ) .E i g h tp a t i e n t sw e r ed i a g n o s e dw i t h
sporadic LAM only and two patients had LAM in asso-
ciation with TSC (patient #2, #7). Mean age at the
time of enrolment was 42.4 ± 11.9 years with an aver-
age time of 4.6 ± 2.9 years (range 0.8 - 10.4 years)
since establishment of diagnosis. Progressive dyspnea
on exertion was the primary event leading to the diag-
nosis in seven cases and recurrent spontaneous pneu-
mothoraces in three patients. Prior to enrollment, 50%
of the patients have been treated with bronchodilators
and 30% received progesterone derivates. No new
bronchodilator therapy was instituted at the time of
enrolment.
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outcome
Time of observation with available pulmonary function
data before initiation of sirolimus therapy was 21.3 ± 5.2
months (range 6.0 - 47.7) and follow-up time after start
of sirolimus was 12.1 ± 2.81 months (range 6.1 - 28.1).
The mean number of available lung function tests before
sirolimus therapy was 6.0 ± 2.4/patient (range 3 - 15)
and 5.9 ± 1.2/patient (3 - 11) during therapy.
Figure 1 depicts the individual mean rate of change of
FEV1 before and after initiation of therapy and figure 2,
and 3 demonstrates the individual course of FEV1 with
and without sirolimus. The overall mean loss of FEV1
amounted to -2.30 ± 0.52 ml/day before therapy. During
the treatment with sirolimus, patients demonstrated a
significant mean FEV1 gain of 1.19 ± 0.26 ml/day (p =
0.001). However, further analysis revealed no significant
positive or negative correlation between the rate of
change of FEV1 before and during sirolimus therapy or
baseline FEV1 and relative increase of FEV1 after initia-
tion of sirolimus, respectively (p > 0.05 each).
Mean FEV1 and Forced Vital Capacity (FVC) at base-
line were 1.12 ± 0.15 l (36.1 ± 4.5%pred.) and 2.47 ±
0.25 l (69.2 ± 6.5%pred.), respectively. Follow-up pul-
monary function tests revealed a significant increase of
FEV1 and FVC at three and six months during sirolimus
therapy in comparison to baseline values (3 months
ΔFEV1: 220 ± 82 ml, p = 0.024; 6 months ΔFEV1: 345 ±
58 ml, p = 0.001); (3 months ΔF V C :3 6 0±1 4 1m l ,p=
0.031; 6 months ΔFVC: 488 ± 138 ml, p = 0.006). How-
ever, we detected no significant difference between three
and six months measurements (table 2). Moreover, no
significant changes of mean total lung capacity (TLC)
Table 1 Characteristics of 10 patients with lymphangioleiomyomatosis
Pat.
ID
age*
(years)
sirolimus therapy
(days)
presence of
angiomyolipoma
No. of
pregnancies
Smoking
history
No. of
pneumothoraces
1 47 218 no 0 no 0
2 39 185 yes 1 no 1
3 28 325 no 0 no 2
4 33 758 no 1 no 1
5 49 749 no 3 no 1
6 39 817 yes 0 no 2
7 48 266 yes 0 yes 0
8 29 191 no 2 yes 3
9 51 295 no 0 no 0
10 58 854 yes 0 yes 0
*at time of enrollment
Figure 1 Mean rate of change of FEV1 before and during
sirolimus therapy. Bars show the individual comparison of mean
rate of change (ml/day) of FEV1 (forced expiratory volume in 1
second) before (black) and during (white) sirolimus therapy for ten
patients.
Figure 2 Changes of FEV1 before and during sirolimus therapy.
Serial individual values of FEV1 (forced expiratory volume in 1
second) before and during sirolimus therapy in ten patients.
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Page 3 of 7after three months (6.57 ± 0.32 l, 125 ± 7.1%pred., p =
0.48) and 6 months (6.64 ± 0.38 l, 126.8 ± 8.7%pred., p
= 0.67) in comparison to baseline values (6.11 ± 0.27 l,
116 ± 5.3%pred.) were noted.
Baseline readings revealed a severe impairment of dif-
fusing capacity (DLCO 28.0 ± 3.4%ped., table 3). How-
ever, there was a small but significant increase in DLCO
after six months as compared to baseline measurements
(ΔDLCO: 4.7 ± 1.2%pred., p = 0.004), whereas blood gas
analysis did not demonstrate a significant change after
three and six months (table 3). Five patients (#4, #5, #7,
#9 and #10) were on long-term oxygen supplementation
at the beginning of the study. In all but one patient (#4),
oxygen therapy was continued throughout the study
period. No additional patients required long-term oxy-
gen therapy during the conduct of the study.
Complete 6-MWD testing at baseline and after six
months of therapy was only available in 5 patients. Only
patients on long-term oxygen supplementation used oxy-
g e nd u r i n g6 - M W Dt e s t i n g( p a t i e n t# 4a n d# 7 ) .S u b -
group analysis for these patients revealed a modest
though significant increase in 6-minute walk distance at
six months (Δ 6-MWD: 49.0 ± 13.1 m, p = 0.02, table 3).
Adverse events
Aphthous ulcers, peripheral edema or deterioration of
kidney function or hemorrhage were not reported. No
patient experienced pneumothoraces or relevant pleural
effusion during the administration of sirolimus and no
deaths occurred at available follow-up.
However, lower respiratory tract infection was
recorded in 5 patients while receiving sirolimus. There
was no evidence for pneumonia in two of these
patients. In these two cases, the clinically mild event
occurred within four weeks after initiation of sirolimus.
No antibiotic therapy, discontinuation of sirolimus or
hospitalization was deemed necessary and the symp-
toms resolved without sequelae. Nevertheless, sirolimus
therapy was permanently stopped because of recurrent
signs of lower respiratory infections with fever and leu-
cocytopenia requiring hospitalization and antibiotic
therapy in three patients (no. 1, no. 7, no. 8) after 218,
266 and 191 days, respectively. A definite distinction
between pneumonia and sirolimus associated pneumo-
nitis was not established and a pathogenic agent was
not identified. After discontinuation of sirolimus and
empiric broad spectrum antibiotic therapy, white blood
count and respiratory symptoms resolved without
sequelae.
However, two of these three patients underwent success-
ful transplantation because of progressive deterioration of
lung function (patient no. 7) and therapy refractory bilat-
eral pneumothoraces (patient no. 8) 58 days and 322 days
after cessation of sirolimus, respectively.
Figure 3 Changes of FEV1 before and during sirolimus therapy.
Serial individual values of FEV1 (forced expiratory volume in 1
second) before and during sirolimus therapy in ten patients.
Table 2 Pulmonary function and 6-Minute-walk-distance characteristics of 10 patients with lymphangioleiomyomatosis
Pat. ID FEV1 (l/% pred.) FVC (l/% pred.)
Baseline 3 months p 6 months p baseline 3 months p 6 months p
1 1.79 62.0 1.39 49.0 2.22 77.6 2.65 77.4 2.75 81.4 3.17 93.2
2 1.51 44.8 1.89 56.1 1.88 55.3 3.02 78.3 3.27 84.8 3.26 84.1
3 1.69 44.3 1.86 48.7 1.98 51.9 2.90 66.1 2.99 67.3 3.12 71.4
4 1.39 43.7 1.84 58.4 2.03 64.4 2.58 71.7 3.06 85.5 3.63 99.3
5 0.34 12.3 0.53 19.1 0.64 23.3 0.78 24.9 1.58 49.6 1.54 48.1
6 1.00 29.8 1.35 41.1 1.41 42.9 2.86 74.1 2.91 76.3 3.56 93.3
7 0.93 34.4 1.22 45.1 1.11 41.3 3.17 99.0 2.99 94.2 2.99 94.2
8 0.85 25.8 1.03 31.3 1.05 31.9 2.38 63.4 3.35 89.1 2.54 67.2
9 0.95 27.6 1.22 41.6 1.30 44.4 2.98 88.5 2.94 86.4 3.18 94.2
10 0.49 22.4 1.03 47.0 1.08 48.9 1.40 52.3 2.48 90.6 2.61 95.5
Mean ±
SEM
1.12 ±
0.15
36.1 ±
4.5
1.34 ±
0.14
44.0 ±
3.7
0.024 1.47 ±
0.17
48.1 ±
4.9
0.001 2.47 ±
0.25
69.2 ±
6.5
2.83 ±
0.16
80.2 ±
4.2
0.031 2.96 ±
0.19
83.9 ±
5.25
0.006
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Encouraged by reports revealing positive effects in some
cases with pulmonary LAM, we decided to start siroli-
mus therapy in patients with impaired pulmonary func-
tion and progressive respiratory disease on an individual
basis. Our data support and extend the previous obser-
vations suggesting that even in an advanced stage of the
disease sirolimus can potentially improve lung function.
In addition, we found improvement of submaximal exer-
cise capacity assessed by 6-MWD in some patients.
However, due to the fact that a significant number of
data is missing and the 6-minute walk test is prone to
error without confirmative measurements our findings
do not allow to draw firm conclusions regarding a rele-
vant functional benefit of sirolimus over time at this
point.
In the absence of an effective alternative treatment,
lung transplantation is an accepted therapy for end-
stage pulmonary LAM and outcome data are compar-
able to those achieved for other indications. However,
due to overall limited long-term survival, lung transplan-
tation may not be considered as a cure for the rather
young cohort of patients affected by LAM [15,16].
Given the fact that TSC1 and TSC2 proteins regulate
signalling through the mTOR pathway and the antiproli-
ferative effects of sirolimus on smooth muscle cell growth,
mTOR inhibition has emerged as a promising target for
therapeutic interventions in pulmonary LAM [17].
This notion is supported by the results of Bissler et al.,
demonstrating a mean increase of FEV1 from baseline of
approximately 120 ml after six and twelve months of
sirolimus therapy in eleven LAM patients. However,
only seven patients had abnormal lung function at the
time of enrolment (moderate airflow obstruction in
three patients and severe reduction of FEV1 in four
patients) in this very important trial and no rate of
decline prior to initiation of therapy was reported [7].
The present report confirms and extends these findings,
in that we found significant improvement of lung func-
tion in a subset of patient with severe airflow obstruc-
tion and documented functional deterioration. Our
findings are in line with a case report of Taille and co-
workers, demonstrating a gain of 570 ml in FEV1 within
six months of sirolimus therapy for pulmonary LAM
starting from a FEV1 baseline of 32% predicted [18].
In contrast, interim data from an ongoing trial of siro-
limus in Great Britain did not indicate an improvement
of pulmonary function in four LAM patients with mild
to severe airflow obstruction despite sirolimus therapy
for twelve months [8]. In this respect, the accompanying
editorial of Paul and Thiele in the New England Journal
of Medicine provides a valuable insight into the molecu-
lar rationale for sirolimus therapy [19]. Nevertheless, the
authors point out that the clinical effects of a pharmaco-
logical treatment for somatic mutations of TSC1-TSC2
c o m p l e x e sh a v et ob ev e r yv a r i a b l eb yn a t u r e .H o w e v e r ,
g i v e nt h es m a l ls a m p l es i z ei no u ro w nw o r ka n dt h e
studies of Bissler et al. and Davies and colleagues, even
differences in statistical techniques to assess response to
therapy may be a crucial factor contributing to outcome
discrepancies [7,8]. Another possible explanation for the
lack of a significant effect of sirolimus may be the fact
that in the study of Davies et al., adverse events resulted
in all but one patient in periods of dose reduction or
cessation [8]. We therefore speculate that in this trial
mean exposure to the study drug was not enough to
achieve an effect on pulmonary LAM. Unfortunately,
significant adverse events including hospitalization due
to relevant lower respiratory tract infections or siroli-
mus-induced pneumonitis have also been frequently
Table 3 Pulmonary function and 6-Minute-walk-distance characteristics of 10 patients with lymphangioleiomyomatosis
Pat. # DLCO (% pred.) pO2 (mmHg) 6 MWD (m)
baseline 3 months p 6 months p baseline 3 months p 6 months p baseline 6 months p
1 46 51 68 67 68 700 730
2 38 37 38 61 67 69 500 530
33 7 4 0 6 2 6 7 6 9
4 26 33 39 55 56 62 420 510
5 1 51 2 1 8 5 24 1 4 8
6 23 25 24 69 67 70 510 535
7 12 15 19 55 50 56 300 370
8 2 23 0 5 96 3
9 3 43 6 3 6 6 06 2 5 6 5 2 5
10 27 32 32 57 64 68 540
Mean ± SEM 28.0 ± 3.4 27.1 ± 3.8 0.15 32.7 ± 3.3 0.004 59.8 ± 1.7 60.1 ± 3.1 0.91 62.9 ± 2.3 0.88 486 ± 65 535 ± 57 0.02
Definition of abbreviations: FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, DLCO = single breath diffusing capacity for carbon
monoxide, pO2 = partial pressure of oxygen, 6-MWD = 6-Minute-Walk-Distance, SEM = standard error of the mean.
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olimus even in the presence of initial functional
improvement during therapy. Moreover, the occurrence
of pneumothoraces as a potential late complication of
sirolimus therapy warrants careful monitoring in future
studies. Of note, we speculate that due to the lack of a
rigorous assessment, our study might have missed a
substantial number of minor adverse events and there-
fore underestimates the overall negative impact of siroli-
mus administration. Beyond that, it must kept in mind
that discontinuation of the drug within several weeks
prior to lung transplantation is mandatory in order to
avoid dehiscence of the bronchial anastomosis due to
impaired wound healing.
In addition the rate of progression of disease is vari-
able with some patients experiencing a long term course
lasting for decades and partially reversible airflow
obstruction further complicating outcome assessment.
In a large cohort of LAM patients with initially only
mild impairment of pulmonary function (mean FEV1
75.2%pred.), the average rate of change in FEV1 was
reported to be only -75 ml/year [20,21]. In contrast, our
own small study population demonstrated a projected
overall loss of 840 ml per year with an initial FEV1 of
36.0%pred. and severe impairment of diffusing capacity.
According to the study of Taveira-DaSilva and collea-
gues, the most important predictors for further func-
tional decline are initially low FEV1 and severely
reduced DLCO. Therefore, it is unlikely that the
observed positive functional responses for both FEV1
and FVC readings in our patients are explained by indi-
vidual variable course of the disease or reversal of air-
flow obstruction alone [22].
Moreover, our therapeutic approach is supported by
the results of the recently published MILES-trial [23].
McCormack and colleagues demonstrated stabilization
and to some extent improvement of lung function para-
meters in LAM patients with moderate lung impair-
ment. Of note, sirolimus was associated with an
acceptable safety profile over a treatment period of
twelve months in comparison to placebo. Nevertheless,
due to the lack of a predefined loss of FEV1 as inclusion
criteria, the subset of patients benefiting most from this
medical intervention remains to be established.
However, we have to take into consideration that the
use of historic pulmonary function tests in our study
increased the risk for a lack of standardisation especially
for bronchodilator testing. In addition, we acknowledge
that the main reason for referral of LAM patients to our
center was evaluation for lung transplantation. So, these
limitations might have resulted in a significant selection
bias overestimating the rate of actual FEV1 loss and the
impact of sirolimus treatment in comparison to the
overall LAM population. Moreover, despite the fact that
progesterone seems not to be effective in reducing the
decline of lung function in LAM patients, we cannot
rule out the possibility that withdrawal of progesterone
therapy might have influenced the subsequent course in
some patients [21].
Conclusions
We clearly recognize the inherent limitations of our
report with respect to our non-prospective design, lack
of a control group, limited sample size and short fol-
low-up time. Despite the substantial risk of hemor-
rhage and renal failure in case of angiomyolipoma,
these complications can usually be managed with med-
ication, dialysis or renal transplantation with an accep-
table long-term outcome. In contrast, the prognosis for
patients with pulmonary LAM can be very limited in
case of disease progression given the overall limited
survival benefit achieved by lung transplantation. The
present study demonstrates that sirolimus administra-
tion for pulmonary LAM can be associated with ser-
ious adverse events. Nevertheless, our data suggest that
the use of mTOR inhibitors might be considered as a
potential therapeutic option in carefully monitored,
rapidly declining LAM patients. However, this report
first of all highlights the urgent need for further
research addressing the efficacy, safety, and dosing of
s i r o l i m u si nt h i sp o p u l a t i o n[ 2 4 ] .
In this respect, future trials are still necessary to guide
management of pulmonary LAM and prevent the rou-
tine use of potentially harmful therapies.
Abbreviation list
DLCO: single breath diffusing capacity for carbon monoxide; FVC: Forced Vital
Capacity; FEV1: forced expiratory volume in 1 second; LAM:
Lymphangioleiomyomatosis; mTOR: mammalian target of rapamycin; 6-MWD:
distance covered in 6 minutes; PFT: Pulmonary function tests; SEM: standard
error of the mean; TSC: tuberous sclerosis complex.
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